Navigation Links
Weighing costs, benefits of HIV treatments
Date:9/15/2009

HANOVER, NH Prevention versus treatment? Cost versus efficacy? So go two of the dilemmas looming over Dartmouth's Paul E. Palumbo, M.D., and his fellow researchers in the race to fight HIV and other infectious diseases in the developing world especially among women and their young children.

"We have this big quandary in resource-limited countries," says Palumbo, a Dartmouth Medical School professor of medicine and pediatrics. "We have a simple approach that is cost-effective, and reduces transmission [of HIV] by 50 percent. The Achilles heel of that approach is that in the mother and in any infant who does become infected, the virus learns to become drug-resistant."

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP). The infants all had previously received a single dose of NVP in liquid form at birth, and their mothers each had taken NVP in the form of a single pill during labor in an attempt to prevent HIV transmission.

In July, IMPAACT leaders presented their findings in South Africa at the inaugural International Workshop on HIV Pediatrics and the International AIDS Society's fifth Conference on HIV Pathogenesis Treatment and Prevention. Chief sponsors of the trial are the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Findings also revealed that the LPV/r arm of the trial showed results so much better that in the spring of 2009, an independent data and safety monitoring board (DSMB) halted the NVP arm and gave the go-ahead for IMPAACT to enroll children who did not receive NVP at birth.

"These findings," NIAID stated in a recent bulletin, "provide clear evidence in support of the current World Health Organization recommendation that HIV-infected infants who have received NVP at birth should be started on an LPV/r-based treatment regimen whenever possible."

But here's the rub: LPV/r is a relatively expensive drug more available in the developed than the developing world, and it must be kept cold a challenge in sub-Saharan Africa and much of India. On the other hand, NVP is relatively cheap and accessible in developing nations.

Breast-feeding presents another challenge: While it can lead to infection of the infant of an HIV-positive mother, the mother's milk also protects the child against many common infections of infancy, Palumbo says. Also, formula feeding to prevent transmission of HIV a common practice in the developed world leaves infants prone to suffer from upper-respiratory infections, diarrhea, and other maladies. According to estimates of the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), more than nine million children younger than 5 are expected to die each year 17 percent from pneumonia, 17 percent from diarrhea, and 7 percent from malaria, as opposed to 1.5 percent from HIV/AIDS. At least 10 percent of enrollees in the IMPAACT study already are or may be suffering from tuberculosis.

That's why, as the trial continues, IMPAACT will examine whether NVP becomes effective again in HIV-positive children after a certain age.

"There's a big, dynamic struggle going on as we speak," Palumbo says. "We're right in the middle of this active debate. The question is, how fast can we do it? Can scientific mandates be translated into practice? Those data are going to be used to inform the prevention and treatment guidelines at WHO. I still don't know how it's going to play out." Palumbo also serves as executive director of the Dartmouth-affiliated DarDar Pediatric Program in Tanzania.


'/>"/>

Contact: David Corriveau
dms.communications@dartmouth.edu
603-653-0771
Dartmouth College
Source:Eurekalert

Related medicine news :

1. Job Stress, Economy Weighing on Americans
2. Weighing the options after life-altering stroke
3. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
4. Lowering sodium consumption could save US $18 billion annually in health costs, study finds
5. Small businesses would see lower costs, more comprehensive coverage from health reform
6. Pelosi: Public Option Best Way to Control Costs, Promote Competition
7. Tevas Patient First Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals
8. Sinking Economy Hit Hard by Soaring Healthcare Costs, Says MedicareSupplementPlans.com
9. Pennsylvania Governor Rendell Ceremonially Signs Four Health Care Bills That Will Reduce Costs, Improve Access and Quality
10. Lumension Integrates With Network Frontiers' Unified Compliance Framework To Simplify Compliance Challenges, Reduce Costs, And Harmonize Controls
11. HMS Urges Healthcare Reform Measures to Manage Costs, Target Resources, Fight Fraud
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In Madeira ... the mainland by a single drawbridge, citizens formed an organization, Madeira Beach United, to ... traffic and change the small town center to a high rise urban environment. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic apparel company ... second pop-up shop for three consecutive weekends. The pop-up shop is a great ... community, a community full of women who appreciate the most premium goods and ...
(Date:5/25/2016)... ... May 26, 2016 , ... The United States Food and Drug ... in both men and women. To date, the company is the first and only ... any adult who suffers with androgenetic alopecia. , “This new level of clearance ...
(Date:5/25/2016)... ... May 25, 2016 , ... Extremity ... Tennessee locations to streamline patient check-in and post visit surveys. , “The Phreesia ... patient care. It has revolutionized the check-in process for our clinic network, providing ...
(Date:5/25/2016)... ... May 25, 2016 , ... A new update to Xsens ... all by utilizing a common Wi-Fi network and a mobile device. When paired with ... location with Wi-Fi, and use a mobile device to control the recording. , ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)... 24, 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei ... ‚ausgezeichneter plus guter , ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) ... positive Daten von der MORA-Studie der Phase III ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: